Ovid Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview

Ovid Therapeutics

10/03/2023 12:41

* Ovid Therapeutics Inc  OVID.OQ   OVID.O  is expected
to show no
change in quarterly revenue when it reports  results on March 13
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Ovid Therapeutics
Inc is
for a loss of 18 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ovid
Therapeutics
Inc is $4.5​, above​ its last closing price of $2.15. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.21       -0.21      -0.17     Beat    20.7
 Jun. 30 2022  -0.25       -0.25      -0.21     Beat    15.6
 Mar. 31 2022  -0.20       -0.21      -0.23     Missed  -11​
 Dec. 31 2021  -0.15       -0.16      -0.10     Beat    38
 ​​Sep.        -0.18       -0.18      -0.17     Beat    7.5
 30 2021                                                
 Jun. 30 2021  -0.15       -0.16      -0.23     Missed  -42​
 Mar. 31 2021  1.39        1.68       2.53      Beat    50.8
 Dec. 31 2020  -0.25       -0.31      -0.34     Missed  -9.7
 This summary was machine generated March 10 at 12:41 GMT.  All
figures in US dollars  unless otherwise stated